Mimedx (MDXG) Cash & Equivalents (2010 - 2026)

Mimedx (MDXG) has 17 years of Cash & Equivalents data on file, last reported at $159.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 50.12% year-over-year to $159.8 million; the trailing twelve-month figure through Mar 2026 stood at $159.8 million (up 50.12% YoY), and the FY2025 full-year result was $166.1 million, up 59.1% from the prior year.
• Cash & Equivalents declined to $159.8 million in Q1 2026, from $166.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $166.1 million in Q4 2025 to a low of $48.5 million in Q1 2024.
• A 5-year average of $94.0 million and a median of $78.8 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents declined 24.27% in 2022 and soared 119.5% in 2025, its largest moves.
• Tracing MDXG's Cash & Equivalents over 5 years: stood at $66.0 million in 2022, then grew by 24.34% to $82.0 million in 2023, then advanced by 27.34% to $104.4 million in 2024, then soared by 59.1% to $166.1 million in 2025, then retreated by 3.82% to $159.8 million in 2026.
• Business Quant data shows MDXG's Cash & Equivalents at $159.8 million in Q1 2026, $166.1 million in Q4 2025, and $142.1 million in Q3 2025.